GENBGenerate Biomedicines, Inc.

Healthcare
$14.35

The financials

Generate Biomedicines, Inc. by the numbers

Generate Biomedicines, Inc. (GENB) reported revenue of $6.3M in Q2 2026 (quarter ended Jun 30, 2026), down 28% from the same quarter a year earlier. That came with net loss of $67M. The next results filing is expected around Nov 5, 2026, a quarter after the last one.

Generate Biomedicines, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$6.3M$8.8M−28%
Operating income−$72M−$48Mn/a
Net income−$67M−$42Mn/a
Diluted EPS−$0.52−$1.62n/a
On our screens:Most shorted stocks

Biotechnology

The closest names by size in the same industry

Compare peers
NKTR+0.81%
Nektar Therapeutics
ZLAB+0.64%
Zai Lab Limited
KOD+6.0%
Kodiak Sciences Inc.
OCUL+0.40%
Ocular Therapeutix, Inc.
SLS+3.5%
SELLAS Life Sciences Group, Inc.
AGIO-0.25%
Agios Pharmaceuticals, Inc.